Neurocrine Biosciences Inc Stock Price, News & Analysis

Neurocrine Biosciences (NBIX) presented a systematic literature review at the 2025 ISPOR Annual Meeting, examining the relationship between glucocorticoid (GC) dosage and adverse clinical outcomes in congenital adrenal hyperplasia (CAH) patients. The study analyzed 105 publications, with 65% focusing on CAH patients.

Key findings revealed that 62% of publications found statistically significant associations between GC dose and clinical outcomes, with 98% of these indicating higher GC doses led to adverse effects, including decreased bone mineral density, increased insulin resistance, and higher body mass index. The most commonly reported outcomes were bone health (43%), cardiometabolic (41%), and height and growth (24%).

Neurocrine Biosciences (NASDAQ: NBIX) has launched "ConnectING with Carnie™," a multimedia awareness campaign featuring Grammy-nominated singer Carnie Wilson. The campaign focuses on tardive dyskinesia (TD), an involuntary movement disorder caused by antipsychotic medications. While Wilson doesn't have TD herself, she will serve as an advocate to reduce stigma and encourage patients to seek treatment.

The initiative aims to empower individuals with TD to discuss their symptoms openly and explore treatment options, including INGREZZA® (valbenazine) capsules. The campaign will feature video interviews and resources on ConnectingWithCarnie.com, sharing stories from TD patients, care partners, and healthcare professionals about their experiences with the condition and its treatment.

Neurocrine Biosciences has launched a Phase 3 registrational program to test NBI-1117568, an oral muscarinic M4 selective orthosteric agonist, for treating adults with schizophrenia. This advancement follows successful Phase 2 results from August 2024.

The Phase 3 trial will be a global, double-blind, placebo-controlled study involving approximately 280 adult patients with schizophrenia experiencing acute symptom exacerbation. The study's primary goal is to measure reduction in the Positive and Negative Syndrome Scale (PANSS), with a secondary focus on the Clinical Global Impression of Severity (CGI-S) scale.

Phase 2 results showed promising outcomes with the 20 mg daily dose, including:

• A significant PANSS score reduction of 7.5 points versus placebo
• An 18.2-point reduction from baseline
• Improvements in secondary endpoints
• Good safety profile with minimal side effects

Neurocrine Biosciences (NBIX) has published a groundbreaking post-hoc analysis in The Journal of Clinical Psychiatry, demonstrating INGREZZA's long-term efficacy and safety in treating tardive dyskinesia (TD) in adults aged 65 and older.

The analysis, pooling data from two 48-week studies (KINECT 3 extension and KINECT 4), included 304 participants, with 55 (18.1%) aged ≥65 years. Key findings show that older adults achieved substantial TD symptom improvements within 8 weeks, sustained through 48 weeks:

• 95% of patients on INGREZZA 80mg showed ≥30% improvement in AIMS scores
• 95% on 80mg demonstrated CGI-TD improvements
• 90% on 80mg reported PGIC improvements

The safety profile remained consistent with no new treatment-emergent adverse events of clinical concern compared to younger adults. Common side effects included urinary tract infection and somnolence, each affecting 6 of 55 older participants.